JNJ - Morgan Stanley sees 15% upside in Amgen in premarket analyst action December, 17 2019 08:54 AM Johnson & Johnson Amgen (NASDAQ:AMGN) resumed with Overweight rating and $280 (15% upside) price target at Morgan Stanley.More news on: Amgen Inc., Hill-Rom Holdings, Inc., Johnson & Johnson, Healthcare stocks news, Stocks on the move, , Read more ...